To directly compare the effects of KRAS and BRAF mutations in a genetic background originally dependent on pathway mutation, Kundu et al. [111] engineered KRAS G12C, G12D, G12V, and G13D mutations in colorectal cancer RKO cells. The gene discussed is KRAS; the disease is colorectal cancer.